- AbTis and ChemExpress have entered a strategic partnership focused on advancing site-selective antibody-drug conjugate (ADC) development using AbClick®.
- The collaboration aims to integrate proprietary conjugation technology with full-spectrum CDMO capabilities for cancer therapies.
AbTis has signed a strategic cooperation agreement with ChemExpress to accelerate the development of next-generation antibody-drug conjugates (ADCs) through the integration of their respective platforms and expertise. The partnership will centre around AbClick®, AbTis’ proprietary site-selective antibody conjugation technology, which offers greater control over critical ADC parameters such as half-life, drug-to-antibody ratio (DAR), and linker-payload stability.
ChemExpress, a China-based company with one-stop R&D and GMP production capabilities in the ADC space, will combine its contract manufacturing expertise with AbTis’ platform to support the development of safer and more effective precision therapies for cancer patients. The collaboration will span from early discovery to commercialisation.
The agreement also supports the broader goal of enhancing the competitiveness of the global ADC industry chain and ensuring that innovative therapies reach patients with unmet medical needs sooner. Both parties intend to deepen the application of site-selective conjugation technology through collaborative innovation.
“We are very pleased to have reached a strategic cooperation with AbTis, which owns the third-generation antibody conjugation technology platform AbClick® with independent intellectual property rights,” said Dr. Zheng Baofu, Chairman of ChemExpress.
